CX1739
Based on 1 Customer Validation
CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury.
For research use only. We do not sell to patients.
- Purity: 99.63%
- CAS No.: 1086377-48-1
- Formula: C13H15N3O3
- Molecular Weight:261.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
CNS-Penetrant Compound Library
HY-L028
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
All iGluR Isoforms
More
Biological Activity
CX1739 binds to the GluA2 LBD-L483Y-N754S AMPA receptor subunit via weak nonpolar interactions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | AUC0-t | AUC0-∞ | T1/2 | Tmax | Cmax | AUC0-∞ (Brain) | T1/2 (Brain) | Tmax (Brain) | Cmax (Brain) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[2] | 10 mg/kg | i.v. | 17.467 mg·h/L | 17.568 mg·h/L | 1.072 h | 0.033 h | 13.275 mg/L | 9.679 mg·h/L | 0.908 h | 0.033 h | 8.295 mg/L |
CX1739 (0.03-0.1 mg/kg, intraperitoneal injection, administered twice: 20 minutes before T1 and 20 minutes before T2) enhances novel object recognition memory in adult Wistar rats[1].
CX1739 (0.03-1 mg/kg; i.p.; single administration) significantly reduces the number of arm entries required for SD rats to locate the third baited arm in the win-shift radial arm maze, indicating improved spatial/working memory[1].
CX1739 (4-10 mg/kg; i.p.; single dose) significantly improves attentional performance and reduces impulsive behavior in hooded Lister rats during the 5-choice serial reaction time task (5CSRTT)[1].
CX1739 (5.6-30 mg/kg; i.p.; single administration) significantly reduces amphetamine-induced hyperactivity in mice in a dose-dependent manner in vivo[1].
CX1739 (5-20 mg/kg; intravenous administration; single bolus dose) partially reverses alfentanil-induced respiratory depression in rats at a dose of 10 mg/kg, while it completely reverses such depression at a dose of 20 mg/kg[1].
CX1739 (30 mg/kg; intravenous injection; single administration) immediately reverses severe acute respiratory depression induced by the opioid agonist 030418, sodium pentobarbital, and ethanol in male SD rats, restoring their respiratory rate to normal levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Long-Evans (male, 250-350 g)[1]
-
Dosage:1 mg/kg; 3 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased mean peak EPSP amplitude by approximately 12% relative to vehicle at 20 min post-tetanic stimulation for the 1 mg/kg dose.
Increased mean peak EPSP amplitude by approximately 22% relative to vehicle at 20 min post-tetanic stimulation for the 3 mg/kg dose.
Did not significantly augment EPSPs before electrical stimulation.
-
Animal Model:Wistar (adult male, 2-3 months, ~230-320 g)[1]
-
Dosage:0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg
-
Administration:i.p.; two doses: 20 min prior to T1 and 20 min prior to T2
-
Result:Increased the novel object recognition index significantly at 0.03 mg/kg and 0.1 mg/kg doses.
Tended to increase recognition memory but did not reach statistical significance at 0.3 mg/kg dose.
-
Animal Model:Sprague-Dawley (male, ~3 months, 310-345 g)[1]
-
Dosage:0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1.0 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced the number of arm entries before finding the third baited arm significantly at 0.3 mg/kg dose.
No other dose comparisons reached statistical significance.
-
Animal Model:hooded Lister (male, 250-310 g at study start)[1]
-
Dosage:4 mg/kg; 10 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased % correct responses, reduced % premature responses, and reduced correct response latency significantly at 4 mg/kg dose.
Increased % correct responses, reduced % premature responses, reduced correct response latency, and increased % omissions at 10 mg/kg dose.
-
Animal Model:CD1 (adult male, 2-3 months, 29-36 g)[1]
-
Dosage:5.6 mg/kg; 10 mg/kg; 18 mg/kg; 30 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced amphetamine-induced locomotor activity in a dose-dependent manner.
Produced a statistically significant reduction at 18 mg/kg dose.
Produced a statistically significant reduction at 30 mg/kg dose.
-
Animal Model:Sprague-Dawley (male, 295-330 g)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.v.; single bolus dose
-
Result:Reversed alfentanil-induced respiratory depression in a dose-dependent manner.
Produced a partial reversal at 10 mg/kg dose.
Produced a full reversal of minute volume to baseline levels at 20 mg/kg dose.
-
Animal Model:Sprague-Dawley (SD) (male, 200-220 g, respiratory depression induced by intravenous opioid agonist 030418)[2]
-
Dosage:30 mg/kg
-
Administration:i.v.; single dose
-
Result:Restored respiratory rate to normal levels.
Chemical Information
-
CAS No. 1086377-48-1
-
Appearance Solid
-
Molecular Weight 261.28
-
Formula C13H15N3O3
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC2=NON=C2C=C1)N(C)C3CCOCC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (382.73 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[2]. Xiao D, et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Med Chem. 2020;12(23):2093-2104. [Content Brief]
[3]. Fusco AF, et al. Acute Administration of Ampakine CX1739 after Cervical Spinal Cord Injury. J Neurotrauma. Published online October 6, 2025. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8273 mL | 19.1366 mL | 38.2731 mL | 95.6828 mL |
| 5 mM | 0.7655 mL | 3.8273 mL | 7.6546 mL | 19.1366 mL | |
| 10 mM | 0.3827 mL | 1.9137 mL | 3.8273 mL | 9.5683 mL | |
| 15 mM | 0.2552 mL | 1.2758 mL | 2.5515 mL | 6.3789 mL | |
| 20 mM | 0.1914 mL | 0.9568 mL | 1.9137 mL | 4.7841 mL | |
| 25 mM | 0.1531 mL | 0.7655 mL | 1.5309 mL | 3.8273 mL | |
| 30 mM | 0.1276 mL | 0.6379 mL | 1.2758 mL | 3.1894 mL | |
| 40 mM | 0.0957 mL | 0.4784 mL | 0.9568 mL | 2.3921 mL | |
| 50 mM | 0.0765 mL | 0.3827 mL | 0.7655 mL | 1.9137 mL | |
| 60 mM | 0.0638 mL | 0.3189 mL | 0.6379 mL | 1.5947 mL | |
| 80 mM | 0.0478 mL | 0.2392 mL | 0.4784 mL | 1.1960 mL | |
| 100 mM | 0.0383 mL | 0.1914 mL | 0.3827 mL | 0.9568 mL |
CX1739 Related Classifications
HY-171844 Related Classifications
Powered by Bioz